EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anti-Müllerian hormone and fertility in women after childhood cancer treatment: Association with current infertility risk classifications

Anna Nyström iD, Helena Mörse, Ingrid Øra iD, Emir Henic, Jacob Engellau, Elinore Wieslander, Andrzej Tomaszewicz, Maria Elfving

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0308827 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Anna Nyström und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences Lund, Paediatrics, Lund University, Lund, Sweden. Hauptthemen laut MEDLINE: Anti-Mullerian Hormone, Neoplasms, Infertility, Female. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Barncancerfonden, the Regional Funding of Skåne, Skånes universitetssjukhus.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To identify childhood cancer survivors (CCSs) at risk of premature ovarian insufficiency (POI) and impaired fertility is important given its impact on quality of life. The aim of this study was to assess ovarian markers and fertility outcomes in adult female CCSs. We used the Swedish and the PanCareLIFE classifications for infertility risk grouping.

Methods

167 CCSs, at median age 34.6 years (19.3–57.8) with a median follow-up time of 25.4 years (11.6–41.3), and 164 healthy matched controls were included in this cross-sectional study. We assessed anti-Müllerian hormone (AMH) levels, antral follicle count (AFC), ovarian volume (OV), and fertility outcomes. Based on gonadotoxic treatments given, CCSs were categorized into infertility risk groups.

Results

The median levels of AMH, AFC and OV were lower in CCSs (1.9 vs. 2.1 ng/ml, 12.0 vs. 13.0, 6.8 vs. 8.0 cm 3 ) compared with controls, although statistically significant only for OV ( p = 0.021). AMH levels in CCSs

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Mullerian HormoneNeoplasmsInfertility, FemaleHumansFemaleAdultYoung AdultMiddle AgedCross-Sectional StudiesFertilityPrimary Ovarian InsufficiencyCancer SurvivorsOvarySwedenCase-Control StudiesChild

Substanzen

Anti-Mullerian Hormone

Autor:innen und Institutionen

  • Department of Clinical Sciences Lund, Paediatrics, Lund University, Lund, Sweden.
  • Paediatric Cardiology, Skåne University Hospital, Lund, Sweden.
  • Paediatric Oncology and Haematology, Skåne University Hospital, Lund, Sweden.
  • Department of Translational Medicine, Reproductive Medicine, Lund University, Malmö, Sweden.
  • Reproductive Medicine, Skåne University Hospital, Malmö, Sweden.
  • Department of Clinical Sciences Lund, Systemic Radiation Therapy, Lund University, Lund, Sweden.

ORCID-Profile: Anna Nyström, Ingrid Øra

Förderung

  • Barncancerfonden
  • the Regional Funding of Skåne
  • Skånes universitetssjukhus

Zitieren

APA

Nyström, A., Mörse, H., Øra, I., Henic, E., Engellau, J., Wieslander, E., Tomaszewicz, A., & Elfving, M. (2024). Anti-Müllerian hormone and fertility in women after childhood cancer treatment: Association with current infertility risk classifications. PLOS ONE. https://doi.org/10.1371/journal.pone.0308827

Vancouver

Nyström A, Mörse H, Øra I, Henic E, Engellau J, Wieslander E, et al. Anti-Müllerian hormone and fertility in women after childhood cancer treatment: Association with current infertility risk classifications. PLOS ONE. 2024. doi:10.1371/journal.pone.0308827

BibTeX
@article{Nystrm2024,
  author = {Nyström, Anna and Mörse, Helena and Øra, Ingrid and Henic, Emir and Engellau, Jacob and Wieslander, Elinore and Tomaszewicz, Andrzej and Elfving, Maria},
  title = {Anti-Müllerian hormone and fertility in women after childhood cancer treatment: Association with current infertility risk classifications},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0308827}
}
Kostenlos starten →